This article contains affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you. See our full affiliate disclosure for details.

Semaglutide vs Tirzepatide: Complete Comparison Guide (2026)

---

How Semaglutide and Tirzepatide Work

Semaglutide and tirzepatide are both injectable medications used to treat type 2 diabetes and obesity, but they work through different mechanisms.

Semaglutide: A GLP-1 Receptor Agonist

Semaglutide mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). When you eat, your body releases GLP-1 to signal fullness to your brain, stimulate insulin release, and slow stomach emptying. Semaglutide activates the same GLP-1 receptors but lasts much longer than the natural hormone.

You may know semaglutide by its brand names:

• Ozempic — injectable, FDA-approved for type 2 diabetes
• Wegovy — injectable, FDA-approved for chronic weight management and cardiovascular risk reduction
• Rybelsus — oral tablet, FDA-approved for type 2 diabetes
• Oral Wegovy — the 25 mg oral tablet approved in late 2025, launched in early 2026 for weight management

Tirzepatide: A Dual GIP/GLP-1 Receptor Agonist

Tirzepatide is a newer medication that activates two receptors instead of one. In addition to GLP-1, it also targets GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action is believed to be the reason tirzepatide produces greater weight loss and blood sugar improvements in clinical trials.

Tirzepatide is available under two brand names:

• Mounjaro — injectable, FDA-approved for type 2 diabetes
• Zepbound — injectable, FDA-approved for chronic weight management and obstructive sleep apnea

If you are new to GLP-1 medications, our beginner's guide to GLP-1 for weight loss covers the fundamentals of how these drugs work and what to expect.

---

Weight Loss: Head-to-Head Clinical Trial Results

The question most people want answered is simple: which one helps you lose more weight? Thanks to several clinical trials and real-world studies, we now have clear data.

SURMOUNT-5: The Definitive Head-to-Head Trial

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, is the largest direct comparison of tirzepatide and semaglutide for weight loss. This phase IIIb open-label trial enrolled 751 adults with obesity (BMI of 30 or higher) but without type 2 diabetes.

Key results at 72 weeks:

• Tirzepatide group (10 mg or 15 mg): average weight loss of 20.2% of body weight
• Semaglutide group (1.7 mg or 2.4 mg): average weight loss of 13.7% of body weight
• The difference of 6.5 percentage points was statistically significant (P<0.001)

To put that in perspective, for someone weighing 250 pounds:

• Tirzepatide would result in roughly 50 pounds lost
• Semaglutide would result in roughly 34 pounds lost

Meta-Analysis Findings

A 2025 systematic review and meta-analysis published in PMC analyzed data from multiple clinical trials and real-world studies. The combined data showed tirzepatide produced significantly greater weight loss than semaglutide, with a mean difference of 4.23 percentage points (95% CI: 3.22–5.25, P<0.01).

The analysis also revealed the advantage was dose-dependent:

• Tirzepatide doses above 10 mg: 6.50 percentage points more weight loss than semaglutide
• Tirzepatide doses of 10 mg or less: 3.89 percentage points more weight loss than semaglutide

Real-World Weight Loss Data

Clinical trials are conducted under controlled conditions with motivated participants. Real-world data tells us what happens in everyday practice.

A 2025 study published in Diabetes, Obesity and Metabolism examined real-world outcomes in an ambulatory care setting and found:

• Tirzepatide was associated with greater weight loss over 6 months in patients without diabetes
• However, in patients with type 2 diabetes, weight loss did not differ significantly between the two medications

This is an important finding. If your primary goal is weight loss and you do not have diabetes, tirzepatide appears to offer a meaningful advantage. If you have type 2 diabetes, the difference may be smaller than clinical trials suggest.

For a broader look at all FDA-approved options, see our comparison of the best GLP-1 medications for weight loss.

---

Blood Sugar Control: A1C Reduction Compared

For people with type 2 diabetes, lowering A1C (a measure of average blood sugar over 2–3 months) is a critical treatment goal. Both medications are highly effective, but tirzepatide has a measurable edge.

SURPASS-2 Trial Results

The SURPASS-2 trial, published in the New England Journal of Medicine in 2021, directly compared tirzepatide to semaglutide 1 mg in 1,879 adults with type 2 diabetes. Results at 40 weeks:

Medication	A1C Reduction	Patients Reaching A1C < 5.7%
Tirzepatide 5 mg	-2.01%	34%
Tirzepatide 10 mg	-2.24%	43%
Tirzepatide 15 mg	-2.30%	51%
Semaglutide 1 mg	-1.86%	20%

The difference is striking. More than half of patients on the highest tirzepatide dose achieved an A1C below 5.7% — a level typically seen in people without diabetes. Only 20% of those on semaglutide reached that threshold.

Real-World A1C Data

A 2025 real-world study published in PMC examined HbA1c outcomes in patients with type 2 diabetes and confirmed that tirzepatide produced greater A1C reductions than semaglutide in routine clinical practice, consistent with the clinical trial findings.

---

Side Effects: What to Expect With Each Medication

Both semaglutide and tirzepatide cause side effects, and the profiles are similar. The most common issues are gastrointestinal — nausea, vomiting, diarrhea, and constipation. For a deeper dive into managing these symptoms, read our complete guide to GLP-1 side effects.

Gastrointestinal Side Effects

Data from the SURPASS-2 trial comparing the drugs head-to-head in type 2 diabetes patients showed:

Side Effect	Tirzepatide (range across doses)	Semaglutide 1 mg
Nausea	17–22%	18%
Diarrhea	13–16%	12%
Vomiting	6–10%	8%

The rates are similar, and most symptoms were mild to moderate in severity. Importantly, GI side effects with both drugs were most common during the dose escalation period and tended to decrease as the body adjusted.

A 2025 meta-analysis in the Annals of Saudi Medicine found that overall GI adverse event rates were higher with tirzepatide (79.8% of participants experienced at least one GI event) compared to semaglutide (30.81%). However, this includes all GI events of any severity, and severe events were uncommon with both medications.

Gallbladder Risks

One notable difference in safety profiles involves the gallbladder. Research has shown that semaglutide increases the risk of gallbladder-related disorders by 1.63 times and cholelithiasis (gallstones) by 2.59 times. Interestingly, this elevated risk was not observed with tirzepatide in the same analysis (PMC, 2025).

Other Side Effects to Watch For

Both medications carry warnings for:

• Pancreatitis — rare but serious; seek immediate medical attention for severe abdominal pain
• Thyroid tumors — both carry a boxed warning about thyroid C-cell tumors observed in animal studies; contraindicated in patients with a personal or family history of medullary thyroid carcinoma
• Hypoglycemia — risk increases when combined with insulin or sulfonylureas
• Injection site reactions — mild redness, swelling, or itching at the injection site

A 2025 study also raised concerns about a potential link between semaglutide and vision problems. Our reporting on the Wegovy blindness risk study covers this emerging research.

---

FDA Approvals and Approved Uses

Understanding which conditions each medication is FDA-approved to treat helps clarify your options and can affect insurance coverage.

Semaglutide FDA-Approved Indications

Brand Name	Form	Approved For
Ozempic	Weekly injection	Type 2 diabetes, cardiovascular risk reduction in T2D patients
Wegovy	Weekly injection	Chronic weight management (BMI 30+ or 27+ with comorbidity), cardiovascular risk reduction in adults with CVD and overweight/obesity
Rybelsus	Daily oral tablet (3, 7, 14 mg)	Type 2 diabetes
Oral Wegovy	Daily oral tablet (25 mg)	Chronic weight management (approved late 2025)

Semaglutide has the broadest range of approved indications. Notably, Wegovy became the first weight loss drug also approved for cardiovascular risk reduction in 2024, based on the SELECT trial showing a 20% reduction in major adverse cardiovascular events (HR 0.80, 95% CI 0.72–0.90) and a 19% reduction in all-cause mortality (HR 0.81, 95% CI 0.71–0.93).

The launch of oral Wegovy in early 2026 is a significant development — read our Wegovy pill vs injection comparison for a detailed breakdown of what changed.

Tirzepatide FDA-Approved Indications

Brand Name	Form	Approved For
Mounjaro	Weekly injection	Type 2 diabetes
Zepbound	Weekly injection	Chronic weight management (BMI 30+ or 27+ with comorbidity), obstructive sleep apnea

Tirzepatide (Zepbound) made history in late 2024 as the first medication ever approved by the FDA specifically for obstructive sleep apnea. However, it does not yet have a cardiovascular risk reduction indication — that trial is ongoing.

---

Cost Comparison: Semaglutide vs Tirzepatide in 2026

Cost is often the deciding factor when choosing between these medications. Here is what you can expect to pay in 2026. For a comprehensive breakdown including savings strategies, see our GLP-1 medication cost guide.

Retail Price Without Insurance

Medication	Monthly Retail Cost
Ozempic (semaglutide)	$900–$1,200
Wegovy (semaglutide)	$1,300–$1,900
Mounjaro (tirzepatide)	$1,000–$1,200
Zepbound (tirzepatide)	$1,000–$1,200

Without insurance, both medications cost roughly $1,000–$1,900 per month at retail pharmacies. Prices vary by dose, pharmacy, and location.

Insurance Coverage

Insurance coverage depends heavily on whether the prescription is for diabetes or weight loss:

For type 2 diabetes:

• Both Ozempic and Mounjaro are covered by most commercial insurance plans
• Typical copays range from $25 to $150 per month
• Medicare Part D covers both for diabetes

For weight loss:

• Coverage for Wegovy and Zepbound is much harder to obtain
• Many commercial insurers still classify obesity drugs as "lifestyle" medications and exclude them
• Medicare has historically been prohibited from covering weight loss drugs, though Wegovy's cardiovascular indication opened a pathway for some patients with CVD

Savings Programs and Discounts

Both manufacturers offer savings programs:

• Eli Lilly (Zepbound): Eligible commercially insured patients may pay as low as $25 for a 1- or 3-month supply
• Novo Nordisk (Wegovy/Ozempic): Similar savings cards available for commercially insured patients

The government has announced that Ozempic, Wegovy, and Zepbound will be available at roughly $350 per month through the TrumpRx direct-to-consumer platform, as well as through Medicare and Medicaid discounts in 2026.

Compounded Versions

Compounded semaglutide has been available at significantly lower prices (sometimes under $200/month), though the FDA has raised safety concerns about unapproved compounded versions. Our guide on compounded semaglutide safety and legality covers this in detail. There is also growing interest in generic semaglutide availability and when prices may drop dramatically.

---

Cardiovascular Benefits

Cardiovascular protection is an increasingly important factor in choosing between these medications.

Semaglutide: Proven Cardiovascular Benefits

The SELECT trial demonstrated that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events (MACE) by 20% in adults with established cardiovascular disease and overweight or obesity, but without diabetes (HR 0.80, 95% CI 0.72–0.90). The trial also showed a 19% reduction in all-cause mortality (HR 0.81, 95% CI 0.71–0.93).

This led to the FDA expanding Wegovy's label in March 2024 to include cardiovascular risk reduction — making it the first weight loss drug with this indication. In 2025, the FDA also expanded Ozempic's label to include cardiovascular risk reduction for adults with type 2 diabetes.

Tirzepatide: Data Still Emerging

As of early 2026, tirzepatide does not have an FDA-approved cardiovascular indication. The SURPASS-CVOT trial evaluating tirzepatide's cardiovascular outcomes in type 2 diabetes patients is ongoing, with results expected in the coming years.

Early signals are promising. The metabolic improvements seen with tirzepatide — greater weight loss, better blood sugar control, and improvements in lipid profiles — suggest cardiovascular benefits are likely. But until the dedicated cardiovascular outcomes trial is complete, semaglutide has the stronger evidence base for heart protection.

For patients with established cardiovascular disease, this distinction matters. If reducing heart attack and stroke risk is a primary concern, semaglutide currently has the proven track record.

For more on the cardiovascular research, see our coverage of how GLP-1 medications may transform heart attack recovery.

---

Beyond Diabetes and Weight Loss: Emerging Uses

Both medications are being studied for conditions far beyond their original approvals.

Semaglutide's Expanding Indications

• MASH (metabolic dysfunction-associated steatohepatitis): Wegovy is under FDA Priority Review for MASH treatment. If approved, it would be the first GLP-1 agent indicated for fatty liver disease.
• Diabetic nephropathy: Ozempic now carries an indication for kidney disease in diabetes patients.
• Addiction and neurological conditions: Early research suggests potential benefits for alcohol use disorder, Alzheimer's disease, and other neurological conditions. These remain investigational.

Tirzepatide's Expanding Indications

• Obstructive sleep apnea: Zepbound is already FDA-approved for moderate-to-severe OSA, a first for any medication in this condition.
• Heart failure with preserved ejection fraction (HFpEF): The SUMMIT trial showed significant improvements in heart failure symptoms and exercise capacity.
• MASH: Eli Lilly is also pursuing a MASH indication for tirzepatide.

Our article on next-gen GLP-1 drugs in the pipeline covers upcoming treatments that may eventually compete with or improve on both semaglutide and tirzepatide.

---

Dosing and Administration

Semaglutide Dosing (Ozempic / Wegovy)

Ozempic (for type 2 diabetes):

• Start: 0.25 mg weekly for 4 weeks
• Increase to: 0.5 mg weekly
• Can increase to: 1 mg, then 2 mg weekly as needed

Wegovy (for weight management):

• Start: 0.25 mg weekly for 4 weeks
• Escalate: 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), 1.7 mg (weeks 13–16)
• Maintenance: 2.4 mg weekly

Tirzepatide Dosing (Mounjaro / Zepbound)

Mounjaro (for type 2 diabetes):

• Start: 2.5 mg weekly for 4 weeks
• Increase to: 5 mg weekly
• Can increase to: 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly as needed

Zepbound (for weight management):

• Start: 2.5 mg weekly for 4 weeks
• Escalate: 5 mg (weeks 5–8), then increase by 2.5 mg every 4 weeks
• Maintenance: 10 mg or 15 mg weekly

Both medications are injected once weekly, on the same day each week. The injection is subcutaneous (under the skin) in the abdomen, thigh, or upper arm. Both use pre-filled autoinjector pens that are relatively easy to use at home.

If you are considering starting treatment, our step-by-step guide to getting a GLP-1 prescription online walks you through the process.

---

Who Should Choose Semaglutide vs Tirzepatide?

There is no one-size-fits-all answer. The best choice depends on your health profile, treatment goals, and practical considerations.

Tirzepatide May Be Better If:

• Maximum weight loss is your primary goal — tirzepatide consistently produces 5–7 percentage points more weight loss than semaglutide in clinical trials
• You have type 2 diabetes and want the best A1C reduction — tirzepatide achieved superior glucose control across all doses in SURPASS-2
• You have obstructive sleep apnea — Zepbound is FDA-approved for OSA
• You are concerned about gallbladder risks — tirzepatide has not shown the elevated gallstone risk seen with semaglutide

Semaglutide May Be Better If:

• You have cardiovascular disease — semaglutide is the only GLP-1 with proven cardiovascular mortality reduction (SELECT trial)
• You prefer an oral option — oral Wegovy (25 mg tablet) launched in early 2026; tirzepatide is injection-only
• Your insurance covers it but not tirzepatide — coverage varies, and some plans have preferred formulary positions for semaglutide
• You want a medication with a longer track record — semaglutide has been on the market longer with more extensive post-marketing safety data

Either Could Work If:

• You have type 2 diabetes without cardiovascular disease
• Weight loss is a goal but not the only goal
• You are open to weekly injections
• Cost is manageable through insurance or savings programs

For help finding a provider, check our ranking of the best online GLP-1 programs or our head-to-head comparison of Hims vs Ro vs Found.

---

How to Switch Between Semaglutide and Tirzepatide

Some patients start on one medication and switch to the other — either because of side effects, inadequate response, or insurance changes. Here is what the evidence says about switching:

• Switching is common and generally safe, but should always be done under medical supervision
• There is no direct dose equivalency between semaglutide and tirzepatide — your doctor will typically start tirzepatide at the lowest dose (2.5 mg) even if you were on a high semaglutide dose
• GI side effects may recur during the transition, as your body adjusts to the new medication
• Weight loss may stall temporarily during the switch and dose escalation period
• Wait at least one week after your last semaglutide injection before starting tirzepatide (and vice versa)

Talk to your prescribing doctor before making any changes to your medication regimen.

---

Muscle Loss and Body Composition

One of the most important — and often overlooked — considerations when comparing these medications is what happens to your body composition during weight loss.

The Muscle Loss Problem

When you lose weight rapidly, a significant portion can come from lean muscle mass rather than fat. Studies suggest that 20–40% of total weight lost on GLP-1 medications may come from lean mass, depending on diet and exercise habits. This matters because:

• Muscle is metabolically active — losing it lowers your resting metabolic rate, making it harder to maintain weight loss long-term
• Functional strength decreases — daily activities, balance, and mobility can be affected, especially in older adults
• "Ozempic face" and loose skin — rapid fat and muscle loss can lead to sagging facial features and excess skin (learn more in our guide to Ozempic face prevention and treatment)

Does Tirzepatide Cause More Muscle Loss?

Because tirzepatide produces greater total weight loss, the absolute amount of lean mass lost may be higher. However, the proportion of fat vs muscle lost appears similar between the two medications. In the SURMOUNT-5 trial, tirzepatide also produced greater reductions in waist circumference, suggesting substantial visceral fat loss.

The key takeaway: regardless of which medication you choose, you should actively work to preserve muscle mass through:

• Adequate protein intake — aim for 1.0–1.2 grams of protein per kilogram of body weight daily (some experts recommend even higher)
• Resistance training — at least 2–3 sessions per week targeting major muscle groups
• Gradual dose escalation — following the recommended titration schedule helps avoid overly rapid weight loss

Our detailed protocol for preventing muscle loss on GLP-1 medications provides a complete exercise and nutrition plan.

---

Long-Term Outcomes: What Happens When You Stop?

A critical question for anyone considering either medication is what happens to weight loss after discontinuation.

Weight Regain After Stopping Semaglutide

The STEP 1 extension trial showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year. This finding has been consistent across multiple studies and highlights that these medications are intended for chronic, ongoing use — not as short-term interventions.

Weight Regain After Stopping Tirzepatide

The SURMOUNT-1 extension study showed a similar pattern. Participants who switched from tirzepatide to placebo after 36 weeks regained a substantial portion of their lost weight by 88 weeks. Those who continued tirzepatide maintained their weight loss.

What This Means for Your Decision

Neither medication offers a permanent "cure" for obesity. Both require ongoing use to maintain results. This makes practical factors like cost, insurance coverage, side effect tolerance, and long-term availability important considerations.

If you are weighing long-term costs, semaglutide may have a slight advantage because:

• Generic semaglutide could become available sooner (Ozempic's patents expire earlier than Mounjaro's)
• The oral Wegovy option may eventually be cheaper to manufacture than injections
• Compounded semaglutide, while controversial, provides a lower-cost alternative

Read our analysis on when generic semaglutide could reach $3 per month for the latest on patent timelines and pricing projections.

---

The Diet Factor: Nutrition on GLP-1 Medications

Regardless of which medication you choose, diet plays a critical role in your results. Both semaglutide and tirzepatide reduce appetite, but the foods you eat still matter for:

• Maintaining muscle mass during weight loss
• Minimizing GI side effects
• Getting adequate protein (a common concern on GLP-1 medications)
• Maximizing long-term health outcomes

Our complete GLP-1 diet guide covers exactly what to eat and avoid while taking either medication. You may also be interested in learning about foods that naturally boost GLP-1 levels as a complementary strategy.

Preventing muscle loss is another critical consideration — especially with tirzepatide's greater weight loss. Our evidence-based protocol for preventing muscle loss on GLP-1 medications is essential reading for anyone on these drugs.

---

Summary Comparison Table

Here is a side-by-side snapshot of the key differences between semaglutide and tirzepatide to help you compare at a glance:

Category	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Brand names (diabetes)	Ozempic, Rybelsus	Mounjaro
Brand names (weight loss)	Wegovy, Oral Wegovy	Zepbound
Average weight loss	13.7% (SURMOUNT-5)	20.2% (SURMOUNT-5)
A1C reduction	-1.86% (SURPASS-2)	-2.30% at 15 mg (SURPASS-2)
Cardiovascular benefit	Proven (SELECT trial, HR 0.80)	Not yet established
Sleep apnea indication	No	Yes (Zepbound)
Oral option available	Yes (Rybelsus, Oral Wegovy)	No
Monthly cost (no insurance)	$900–$1,900	$1,000–$1,200
Common GI side effects	Nausea 18%, diarrhea 12%	Nausea 17–22%, diarrhea 13–16%
Gallstone risk	Elevated (2.59x)	Not elevated
Injection frequency	Once weekly	Once weekly
Manufacturer	Novo Nordisk	Eli Lilly
First FDA approval	2017 (Ozempic)	2022 (Mounjaro)

---

Frequently Asked Questions

Is tirzepatide more effective than semaglutide for weight loss?

Yes, based on current clinical evidence. The SURMOUNT-5 head-to-head trial showed tirzepatide produced an average weight loss of 20.2% compared to 13.7% with semaglutide over 72 weeks in patients with obesity without diabetes (NEJM, 2025). A meta-analysis confirmed tirzepatide produces approximately 4–7 percentage points more weight loss than semaglutide across multiple studies. However, individual responses vary, and some patients do better on semaglutide depending on their specific health profile and how they tolerate each medication.

Are the side effects of tirzepatide worse than semaglutide?

The side effect profiles are similar. Both medications primarily cause gastrointestinal symptoms — nausea, diarrhea, vomiting, and constipation — which are usually mild to moderate and improve over time. In the SURPASS-2 trial, nausea rates were 17–22% for tirzepatide and 18% for semaglutide. One key difference: semaglutide carries a higher risk of gallbladder-related disorders (1.63x increased risk) and gallstones (2.59x), while this risk was not observed with tirzepatide.

Can I switch from Ozempic to Mounjaro (or vice versa)?

Yes, switching between semaglutide and tirzepatide is possible and done regularly in clinical practice. Your doctor will typically have you stop one medication and wait at least one week before starting the other at the lowest available dose. You will need to go through dose escalation again with the new medication, and GI side effects may temporarily return during the transition. Never switch medications without consulting your prescribing physician.

Does insurance cover semaglutide and tirzepatide for weight loss?

Coverage varies significantly. For type 2 diabetes, both Ozempic and Mounjaro are covered by most commercial insurance and Medicare Part D. For weight loss, coverage is much more limited — many insurers still exclude obesity medications. Wegovy has broader weight loss coverage than Zepbound due to its cardiovascular risk reduction indication. In 2026, the TrumpRx program aims to make these medications available at roughly $350/month through Medicare, Medicaid, and a direct-to-consumer platform. Manufacturer savings cards can reduce copays to as low as $25/month for eligible commercially insured patients.

Which is better for type 2 diabetes — semaglutide or tirzepatide?

Both are excellent options for type 2 diabetes, but tirzepatide demonstrated superior A1C reduction in the SURPASS-2 head-to-head trial. Tirzepatide 15 mg reduced A1C by 2.30 percentage points compared to 1.86 for semaglutide 1 mg, and 51% of patients on tirzepatide 15 mg achieved a normal A1C below 5.7% versus 20% on semaglutide. However, semaglutide has proven cardiovascular benefits (20% MACE reduction in the SELECT trial), which may make it the better choice for diabetes patients with existing heart disease. The right medication depends on your complete health picture, and your endocrinologist can help determine the best fit.

---

The Bottom Line

Both semaglutide and tirzepatide are transformative medications for weight loss and type 2 diabetes. The clinical evidence is clear: tirzepatide produces greater weight loss and superior A1C reductions, while semaglutide offers proven cardiovascular protection and the convenience of an oral option.

The "best" medication is the one that fits your specific health needs, insurance situation, and treatment goals. Work with your healthcare provider to evaluate your complete medical history and determine which option gives you the best chance of long-term success.

The GLP-1 medication landscape is evolving rapidly. New formulations, expanded indications, and potentially lower-cost options are on the horizon. Whatever you choose today, stay informed as new data emerges — the best option for you may change as more evidence becomes available.

For more information about your GLP-1 options, explore our GLP-1 medication directory for detailed profiles of every FDA-approved medication.

---

Related Reading

• Best GLP-1 Medications for Weight Loss in 2026
• GLP-1 Medicare Coverage in 2026: What's Covered, Who Qualifies, and How to Apply
• Wegovy vs Ozempic: Same Drug, Different Uses

---

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists carry risks and are not appropriate for everyone. Individual results vary. Discuss the benefits and risks with your doctor to determine the best treatment plan for your specific situation.

-- The GLP-1 Daily Team